Aaron C. Logan, MD, PhD, discusses the FDA approval of the obe-cel in relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
Aaron C. Logan, MD, PhD, University of California San Francisco
Advertisement
Articles by Aaron C. Logan, MD, PhD, University of California San Francisco
Aaron C. Logan, MD, PhD, discusses the potential use of obe-cel as definitive treatment in adult relapsed/refractory B-ALL.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Imlunestrant Plus Abemaciclib for ER+, HER2–, ESR1-Mutated Metastatic Breast Cancer
2
CHMP Recommends Label Expansion of Melflufen to Third-Line Lenalidomide-Refractory Multiple Myeloma
3
Phase 1 Data Support DAWN-303’s Evaluation of INCB161734 in Frontline KRAS G12D–Mutated PDAC
4
Fast-Moving Treatment Advances Shape B-Cell Lymphoma Care
5